Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
Bradley Maron, Editor-in-Chief of Circulation at American Heart Association, shared a post on LinkedIn about a recent article by Jake Silberg, published in Circulation, adding:
”This Week in Circulation:
This week’s feature on agentic and generative AI in drug discovery is already generating real conversation — including from the authors themselves.
Dr. James Zou and colleagues discuss how AI is changing therapeutic development. They break down a complicated topic into clear terms — extremely exciting, and extremely relevant to cardiovascular medicine.
The piece walks through how AI is starting to reshape three key stages of cardiovascular drug development: target selection, therapeutic design, and clinical trial recruitment. Congratulations to Jake Silberg, Peter Eckmann, Joseph Boen, and James Zou on a piece that’s clearly striking a nerve with the field.
Here’s why it matters: the tools are early, and the authors are candid about that — but the direction of travel is one every translational scientist should be watching.”
Title: Agentic and Generative AI for Drug Discovery
Authors: Jake Silberg, Peter Eckmann, Joseph Boen, James Zou
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian